Pravastatin (sodium)
Modify Date: 2025-08-21 18:31:27
Pravastatin (sodium) structure
|
Common Name | Pravastatin (sodium) | ||
|---|---|---|---|---|
| CAS Number | 81131-70-6 | Molecular Weight | 446.51 | |
| Density | N/A | Boiling Point | 634.5ºCat 760 mmHg | |
| Molecular Formula | C23H35NaO7 | Melting Point | 171.2-173 °C | |
| MSDS | USA | Flash Point | 213.2ºC | |
Use of Pravastatin (sodium)Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.Target: HMG-CoA reductasePravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight-loss for lowering cholesterol and preventing cardiovascular disease.Pravastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is recommended to be used only after other measures such as diet, exercise, and weight reduction have not improved cholesterol levels.The evidence for the use of pravastatin is generally weaker than for other statins. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40mg daily (a common starting dose) and those receiving usual care. |
| Name | pravastatin sodium |
|---|---|
| Synonym | More Synonyms |
| Description | Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.Target: HMG-CoA reductasePravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight-loss for lowering cholesterol and preventing cardiovascular disease.Pravastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is recommended to be used only after other measures such as diet, exercise, and weight reduction have not improved cholesterol levels.The evidence for the use of pravastatin is generally weaker than for other statins. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40mg daily (a common starting dose) and those receiving usual care. |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 634.5ºCat 760 mmHg |
|---|---|
| Melting Point | 171.2-173 °C |
| Molecular Formula | C23H35NaO7 |
| Molecular Weight | 446.51 |
| Flash Point | 213.2ºC |
| PSA | 124.29000 |
| LogP | 2.44040 |
| Storage condition | 2-8°C |
| Water Solubility | H2O: 19 mg/mL |
| Hazard Codes | F: Flammable;C: Corrosive; |
|---|---|
| Risk Phrases | R11 |
| Safety Phrases | 16-26-36/37/39-45 |
| RIDADR | 3077 |
| WGK Germany | 2 |
| RTECS | QJ7185000 |
| Packaging Group | III |
| Hazard Class | 9 |
| HS Code | 2932999099 |
|
~87%
Pravastatin (sodium) CAS#:81131-70-6 |
| Literature: BIOCON LIMITED Patent: WO2005/19155 A1, 2005 ; Location in patent: Page/Page column 8 ; |
|
~%
Pravastatin (sodium) CAS#:81131-70-6 |
| Literature: US2005/113446 A1, ; Page/Page column 6 ; |
| Precursor 2 | |
|---|---|
| DownStream 1 | |
| HS Code | 2932999099 |
|---|---|
| Summary | 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, sodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (1:1) |
| 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[[(2S)-2-methyl-1-oxobutyl]oxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- |
| Natrium-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoat |
| Oliprevin |
| Sodium (+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(S)-2-methylbutyryloxy]-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate |
| MFCD00887601 |
| Sodium (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate |
| Sodium (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthalenyl]heptanoate |
| Vasten |
| [1S-[1a(bS*,dS*),2a,6a,8b(R*),8aa]]-1,2,6,7,8,8a-Hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid Monosodium Salt |
| 3b-Hydroxycompactin Sodium Salt |
| Pravastatin sodium |
| Pravastatin (sodium) |